1. Indications and Usage
\nMultiple Sclerosis (MS):
\nTreatment to improve walking speed in adult patients with multiple sclerosis.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Oral Use ONLY.
\nRecommended Dosage:
\nStandard Dose: 10 mg every 12 hours (20 mg\/day).
\nAdministration: Swallow tablets whole. Do not crush, chew, or dissolve the tablets, as this destroys the sustained-release mechanism.
\nFrequency: Do not exceed one 10 mg tablet every 12 hours.
\nCritical Administration Instructions:
\nEmpty Stomach: Should be taken on an empty stomach (do not take with food). Taking with food increases peak plasma levels and the risk of side effects.
\nResponse Assessment: Treatment should be started on a trial basis. Efficacy is usually assessed within 2\u20134 weeks. If no improvement in walking speed is observed, the drug should be discontinued.
\nRenal Adjustment: Contraindicated in patients with moderate to severe renal impairment (Creatinine Clearance < 50 mL\/min).
\n3. Mechanism of Action
\nPotassium Channel Blockade:
\nFampridine is a broad-spectrum potassium (K+) channel blocker.
\nRestoration of Conduction:
\nDemyelination: In MS, the myelin sheath covering nerve fibers is damaged, causing potassium to leak out of the axons. This leak prevents electrical signals from propagating effectively.
\nBlocking Leak: By blocking the exposed potassium channels, Fampridine prolongs the action potential.
\nTherapeutic Result: This allows electrical signals to conduct more effectively past the damaged areas, thereby improving nerve conduction and clinical walking speed.
\n4. Safety and Warnings
\nSeizures (Boxed Warning):
\nFampridine increases the risk of seizures.
\nAction: Discontinue immediately if a seizure occurs.
\nRenal Impairment:
\nThe drug is primarily excreted unchanged by the kidneys. Accumulation occurs in patients with renal dysfunction, significantly increasing seizure risk.
\nUrinary Tract Infections:
\nA common side effect; monitor for symptoms like dysuria or frequency.
\n5.Adverse Reactions
\nMost Common:
\nUrinary tract infection, insomnia, headache, dizziness, nausea, back pain, asthenia (weakness), and balance disorder.
\n6.Drug Interactions
\nOCT2 Inhibitors (Contraindicated):
\nConcomitant use with drugs that inhibit Organic Cation Transporter 2 (OCT2), such as Cimetidine, is contraindicated as it significantly increases fampridine plasma concentrations.
\nOther Potassium Channel Blockers:
\nDo not use with other drugs containing 4-aminopyridine (e.g., Dalfampridine).
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Fampridine (4-Aminopyridine).
\nAvailable Strength: 10 mg tablets.
\nAppearance: White to off-white, capsule-shaped tablets.
\nStorage: Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u201330\u00b0C (59\u201386\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u590d\u5f7c\u80fd \u00ae(Fampyra\u00ae )
\nGeneric Name: Fampridine
\nStrength: 10 mg per tablet, 56 tablets per box
\nManufacturer: Alkermes Pharma Ireland Ltd.
\nMarketing Authorization Holder: Biogen Netherlands B.V.
\nDomestic Responsible Entity: Biogen Biotech (Shanghai) Co., Ltd.
\nApproval Date in China: May 14, 2021
\nRegistration Number: \u56fd\u836f\u51c6\u5b57HJ20210005
\nStorage: Store at controlled room temperature (15\u201330\u00b0C), keep tightly sealed and protected from light and moisture. Refer to the package insert for detailed storage and handling instructions.<\/p>\n
Price&Cost:Contact Us now for the best price of Fampridine \uff08Fampyra\uff09<\/p>\n","protected":false},"featured_media":4084,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-4083","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n